Merck & Company, Inc. (MRK) – Sales growth was led by China in the quarter

in on July 29, 2019

Worldwide sales for Merck increased by 8% to $10.8bn in Q1FY19, excluding the negative impact from foreign exchange, sales grew 11%, driven by growth in Oncology and Vaccines. GAAP EPS were $1.12 for the quarter and non-GAAP EPS increased by 16% to $1.22 for the quarter.

Number of Pages – 43


Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 – Results Overview

–Q1FY19 – Segment Performance

–Q1FY19– R&D Update

–FY19 – Guidance and Conclusion

–GAAP to Non-GAAP Reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per-share Items and Key ratios

–Key Cash Flow Items

–P/E Band

Product Performance and Key Developments



–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

Release Information

  • Released

    July 29, 2019

  • Last Updated

    July 29, 2019